This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A compound according to the general Formula (I)




(I)

the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof ~~and~~ **or** the *N*-oxide form thereof, wherein:

X is $CH_2$, N-$R^7$, S or O ;

$R^7$ is selected from the group of hydrogen, alkyl, Ar, Ar-alkyl, alkylcarbonyl, alkyloxycarbonyl and mono- and di(alkyl)aminocarbonyl;

$R^1$ and $R^2$ are each selected from the group of hydrogen, halo, hydroxy, -$OSO_2H$, –$OSO_2CH_3$, alkyloxy, alkyloxyalkyloxy, alkyloxyalkyloxyalkyloxy, tetrahydrofuranyloxy, alkylcarbonyloxy, alkyloxyalkylcarbonyloxy, pyridinylcarbonyloxy, alkylcarbonyloxyalkyloxy, alkyloxycarbonyloxy, alkenyloxy, alkenyl-carbonyloxy, mono- or di(alkyl)aminoalkyloxy, –N-$R^{10}R^{11}$, alkylthio, Alk and Het,

with the proviso that at least one of $R^1$ and $R^2$ is selected from the group consisting of Alk and Het, wherein

Alk is cyano, CN-OH, CN-oxyalkyl, alkyl, alkyloxyalkyl, alkyloxyalkyloxyalkyl, alkyloxyalkyloxyalkyloxyalkyl, alkylcarbonylalkyl, alkylcarbonyloxyalkyl, alkyloxycarbonylalkyl, Ar-alkyl, Ar-carbonylalkyl, Ar-oxyalkyl, mono- or di(alkyl)aminoalkyl, mono- or di(alkylcarbonyl)aminoalkyl, mono- or di(alkyl)aminocarbonylalkyl, Het-alkyl, formyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkylcarbonyl, mono- or di(alkyl)aminocarbonyl, Ar-carbonyl and Ar-oxycarbonyl ;

Ar is phenyl or naphthyl, optionally substituted with one or more halo, cyano, oxo, hydroxy, alkyl, formyl, alkyloxy or amino radicals.

Het is a heterocyclic radical selected from the group consisting of $Het^1$, $Het^2$ and $Het^3$ ;

$Het^1$ is an aliphatic monocyclic heterocyclic radical selected from the group consisting of pyrrolidinyl, dioxolyl, imidazolidinyl, pyrrazolidinyl, piperidinyl, dioxyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl and tetrahydrofuryl ;

$Het^2$ is a semi-aromatic monocyclic heterocyclic radical selected from the group consisting of 2H-pyrrolyl, pyrrolinyl, imidazolinyl and pyrrazolinyl ;

$Het^3$ is an aromatic monocyclic heterocyclic radical selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl and triazinyl; or an aromatic bicyclic heterocyclic radical selected from the group consisting of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothienyl ;

wherein each $Het^1$, $Het^2$ and $Het^3$-radical may optionally be substituted on either a carbon or heteroatom with halo, hydroxy, alkyloxy, alkyl, Ar, Ar-alkyl, formyl, alkylcarbonyl or pyridinyl ;

$R^{10}$ and $R^{11}$ are each, independently from each other, selected from the group consisting of hydrogen, alkyl, Ar, Ar-alkyl, pyrrolidinylalkyl, piperidinylalkyl, homopiperidinylalkyl, piperazinylalkyl, morpholinylalkyl, mono- or di(alkyl)aminoalkyl, alkylcarbonyl, alkenylcarbonyl, Ar-carbonyl, pyridinylcarbonyl, alkyloxycarbonyl, mono- or di(alkyl)aminocarbonyl, mono- or di(Ar)aminocarbonyl, mono- or di(alkyloxycarbonylalkyl)aminocarbonyl, pyrrolidinylcarbonyl, aminoiminomethyl, alkylaminoiminomethyl, *N*-benzylpiperazinyliminomethyl, alkylsulphonyl and Ar-sulphonyl ; or

$R^{10}$ and $R^{11}$ may be taken together and with the N may form a monovalent radical selected from the group of




and

;

wherein :

$R^{12}$ is selected from the group consisting of hydrogen, alkyl, Ar, Ar-alkyl, Ar-alkenyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkylcarbonyl and mono- or di(alkyl)aminocarbonyl ;

each ring being optionally substituted with q radicals $R^{13}$, each radical independently from each other selected from the group of alkyl, oxo, Ar, Ar-alkyl, Ar-alkenyl and alkyloxycarbonyl and q being an integer ranging from 0 to 6 ; or

$R^1$ and $R^2$ may be taken together to form a bivalent radical $-R^1-R^2-$ selected from the group consisting of $-CH_2-CH_2-CH_2-CH_2-$, $-CH=CH-CH_2-CH_2-$, $-CH_2-CH_2-CH=CH-$, $-CH_2-CH=CH-CH_2-$ and $-CH=CH-CH=CH$;

a and b are asymmetric centers ;

$(CH_2)_m$ is a straight hydrocarbon chain of m carbon atoms, m being an integer ranging from 1 to 4 ;

Pir is a radical according to any one of Formula (IIa), (IIb) or (IIc)


(II)

(a) (b) (c)

optionally substituted with n radicals $R^8$, wherein :

each $R^8$ is independently from each other, selected from the group of hydroxy, amino, nitro, cyano, halo and alkyl ;

n is an integer ranging from 0 to 5 ;

$R^9$ is selected from the group consisting of hydrogen, alkyl and formyl;

$R^3$ represents an optionally substituted aromatic homocyclic or heterocyclic ring

system together with an optionally substituted and partially or completely hydrogenated hydrocarbon chain of 1 to 6 atoms long with which said ring system is attached to the Pir radical and of which may contain one or more heteroatoms selected from the group of O, N and S ;

alkyl represents a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, optionally substituted with one or more halo, cyano, oxo, hydroxy, formyl or amino radicals ;

alkenyl represents a straight or branched unsatured hydrocarbon radical having one or more double bonds, optionally substituted with one or more halo, cyano, oxo, hydroxy, formyl or amino radicals ; and

halo is fluoro, chloro, bromo and iodo.

2 (Previously Presented) The compound according to claim 1, wherein $R^3$ is a radical according to any one of Formula (IIIa), (IIIb) or (IIIc)




(a) (b) (c)

wherein :

d is a single bond while Z is a bivalent radical selected from the group consisting of $-CH_2-$, -C(=O)-, -CH(OH)-, -C(=N-OH)-, –CH(alkyl)-, -O-, -S-, -S(=O)-, -NH- and –SH-; or d is a double bond while Z is a trivalent radical of formula =CH- or =C(alkyl)- ;

A is a 5- or 6-membered aromatic homocyclic or heterocyclic ring, selected from the group consisting of phenyl, pyranyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, oxadiazolyl and isoxazolyl ;

p is an integer ranging from 0 to 6 ;

$R^4$ is alkyl;

$R^5$ is selected from the group consisting of hydrogen, alkyl, Ar, biphenyl, halo and cyano ; or

$R^4$ and $R^5$ may be taken together to form a bivalent radical $-R^4-R^5-$ selected from the group consisting of $-CH_2-$, =CH-, $-CH_2-CH_2-$, -CH=CH- , -O-, -NH-, =N-, -S-, $-CH_2N(-alkyl)-$, $-N(-alkyl)CH_2-$, $-CH_2NH-$, $-NHCH_2-$, -CH=N-, -N=CH-, $-CH_2O-$ and $-OCH_2-$ ;

each $R^6$ is independently from each other, selected from the group consisting of hydroxy, amino, nitro, cyano, halo, carboxyl, alkyl, Ar, alkyloxy, Ar-oxy, alkylcarbonyloxy, alkyloxycarbonyl, alkylthio, mono- and di(alkyl)amino, alkylcarbonylamino, mono- and di(alkyl)aminocarbonyl, mono- and di(alkyl)aminocarbonyloxy, mono- and di(alkyl)aminoalkyloxy ; or

two vicinal radicals $R^6$ may be taken together to form a bivalent radical $-R^6-R^6-$ selected from the group consisting of $-CH_2-CH_2-O-$, $-O-CH_2-CH_2-$, $-O-CH_2-C(=O)-$, $-C(=O)-CH_2-O-$, $-O-CH_2-O-$, $-CH_2-O-CH_2-$, $-O-CH_2-CH_2-O-$, -CH=CH-CH=CH-, -CH=CH-CH=N-, -CH=CH-N=CH-, -CH=N-CH=CH-, -N=CH-CH=CH-, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-C(=O)-$, $-C(=O)-CH_2-CH_2-$, $-CH_2-C(=O)-CH_2-$ and $-CH_2-CH_2-CH_2-CH_2-$ and

$R^{16}$ is selected from the group consisting of hydrogen, alkyl, Ar and Ar-alkyl.

3. (Previously Presented) The compound according to claim 2, wherein X=O ; m = 1 ; Pir is a radical according to Formula (IIa) wherein n =0 ; $R^3$ is a radical according to Formula (IIIb) wherein d is a double bond while Z is a trivalent radical of formula =CH-, A is a phenyl ring, $R^4$ is alkyl, $R^5$ and $R^{16}$ are each hydrogen, $R^6$ is hydrogen or halo and p = 1.

4. (Previously Presented) The compound according to claim 1 wherein at least one of $R^1$ and $R^2$ is selected from the group consisting of cyano optionally substituted with hydroxy or alkyloxy ; alkyl ; hydroxyalkyl ; aminoalkyl ; alkyloxyalkyl ; alkyloxyalkyloxyalkyloxyalkyl ; alkylcarbonyloxyalkyl ; Ar-oxyalkyl ; mono- or di(alkyl)aminoalkyl, the alkyl radicals optionally substituted with hydroxy ; mono- or di(alkylcarbonyl)aminoalkyl ; mono- or di(alkyl)aminocarbonyl ; piperidinylalkyl ; morpholinylalkyl ; and thienyl optionally substituted with alkylcarbonyl.

5. (Previously Presented) The compound according to claim 1 selected from the group consisting of:

- 8-Methoxy-7-methyl-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazole;
- {8-Methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazol-7-yl}-methanol;
- 7-Methoxymethyl-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazole;
- 8-Methoxy-7-(2-methoxy-ethoxymethoxymethyl)-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazole;
- Acetic acid 8-methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazol-7-ylmethyl ester;
- 8-Methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-7-phenoxymethyl-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazole;
- 2-(Methyl-{3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazol-7-ylmethyl}-amino)-ethanol;
- 8-Methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-7-morpholin-4-ylmethyl-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazole;
- 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazole-7-carbaldehyde oxime;
- 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazole-7-carbaldehyde O-methyl-oxime;
- 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazole-7-carbonitrile;
- *N*-{3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazol-7-ylmethyl}-acetamide;
- 8-Methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazole-7-carboxylic acid ethylamide;

and

- 1-(5-{8-Methoxy-3-[4-(2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-*3H*-chromeno[4,3-c]isoxazol-7-yl}-thiophen-2-yl)-ethanone.

6. (Original) A compound which is degraded *in vivo* to yield a compound according to claim 1.

7. (Canceled)

8. (Canceled)

9. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient a therapeutically effective amount of a compound according to claim 1.

10. (Canceled).

11. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient a therapeutically effective amount of a compound according to claim 1 and one or more other compounds selected from the group consisting of antidepressants, anxiolytics and antipsychotics and anti-Parkinson's disease drugs .

12. (Canceled).

13.-16. (Canceled).